EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience

Kamil Deveci, Esra Yildizhan, Ali Unal

Hemato · 13.08.2026 · 7 (3) · 27

DOI: 10.3390/hemato7030027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, online erschienen am 13.08.2026. Verfasst von Kamil Deveci und 2 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment strategies for myelodysplastic syndromes (MDS) range from supportive care to disease-modifying therapies, depending on risk stratification and patient characteristics. Hypomethylating agents (HMAs) remain the standard treatment for higher-risk disease, whereas allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative option. This study evaluated real-world survival outcomes and prognostic factors in patients with MDS treated with HMAs or allo-HSCT.

Methods

A total of 79 patients with MDS who received azacitidine, decitabine, or allo-HSCT were retrospectively analyzed. Overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards analyses. To address potential immortal time bias, a prespecified 6-month landmark analysis was additionally performed.

Results

Median OS was 14.9 months (95% CI, 9.9–20.0) with azacitidine, 10.0 months (95% CI, 6.8–13.2) with decitabine, and 48.0 months (95% CI, 19.9–76.1) after allo-HSCT. Patients undergoing allo-HSCT were significantly younger and had better ECOG performance status than those receiving HMAs. After adjustment for age, ECOG performance status, and IPSS-R risk category, treatment modality remained significantly associated with OS in the multivariable Cox regression model. In the prespecified 6-month landmark analysis, the survival advantage associated with allo-HSCT remained significant, although the adjusted association was attenuated.

Conclusions

In this real-world cohort of actively treated patients with MDS, allo-HSCT was associated with longer overall survival than HMAs. Although this association persisted after adjustment for major clinical confounders and in a landmark analysis addressing immortal time bias, residual confounding related to treatment selection cannot be excluded. These findings should therefore be interpreted as an association rather than evidence of a causal treatment effect.

Zitieren

APA

Deveci, K., Yildizhan, E., & Unal, A. (2026). Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience. Hemato, 7(3), 27. https://doi.org/10.3390/hemato7030027

Vancouver

Deveci K, Yildizhan E, Unal A. Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience. Hemato. 2026;7(3):27. doi:10.3390/hemato7030027

BibTeX
@article{Deveci2026,
  author = {Deveci, Kamil and Yildizhan, Esra and Unal, Ali},
  title = {Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience},
  journal = {Hemato},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {27},
  doi = {10.3390/hemato7030027}
}
Kostenlos starten →